Clinical Trial

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Study acronym: PIVOT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2025-06-27
Trial Details
NCT Number NCT06717958
Lead Sponsor Technische Universität Dresden
Conditions AML, MDS
Enrollment 76 participants
Start Date 2025-06-17
Primary Completion 2029-10-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-02